|
Lupus Erythematosus, Systemic
|
|
0.010 |
GeneticVariation
|
BEFREE |
Significant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta) = 6.6×10(-8), OR = 1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta) = 2.9×10(-7), OR = 1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E.
|
21637784 |
2011 |
|
Low Vision
|
|
0.010 |
GeneticVariation
|
BEFREE |
The common variant in the human complement Factor H gene (CFH), with Tyr402His, is linked to age-related macular degeneration (AMD), a prevalent disorder leading to visual impairment and irreversible blindness in elderly patients.
|
17399790 |
2007 |
|
Lobular Neoplasia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Serum CFH autoantibodies and CFH Tyr402His were screened in the 241 LN patients.
|
22956549 |
2012 |
|
Kidney Failure, Chronic
|
|
0.010 |
GeneticVariation
|
BEFREE |
Multivariate logistic regression analysis showed that Y402H genotype was independently associated with cardiovascular comorbidity in ESRD patients.
|
19428307 |
2009 |
|
Ischemic stroke
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast to expected results, we found no association of Y402H polymorphism with risk of atherothrombosis (adjusted: myocardial infarction, OR=1.09, 95%CI 0.88-1.36, p=0.43; ischaemic stroke, OR=1.11, 95%CI 0.81-1.54, p=0.52; venous thromboembolism, OR=1.41, 95%CI 0.88-2.24, p=0.15), nor with baseline plasma C-reactive protein levels [median (interquartile range) mg/L: YY, 1.39 (0.70-2.60); YH, 1.10 (0.57-2.16); HH, 1.00 (0.48-1.79); p=0.14].
|
16229850 |
2006 |
|
Impaired cognition
|
|
0.010 |
GeneticVariation
|
BEFREE |
The C3F and Y402H polymorphisms are strong independent predictors of moderate-to-severe neurocognitive dysfunction at 1 day following CEA.
|
20841369 |
2011 |
|
Hypertensive disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study.
|
18292760 |
2008 |
|
Hypertensive disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
However, no significant association between rs1061170 (Y402H) and blood pressure or hypertension risk was observed (P≥0.259).
|
22848687 |
2012 |
|
Hypercholesterolemia, Familial
|
|
0.010 |
GeneticVariation
|
BEFREE |
We determined whether or not the Y402H polymorphism influenced CVD risk in a multicentre cohort study involving 2,016 unrelated patients with familial hypercholesterolaemia (FH), who have an extremely increased susceptibility to premature CVD.
|
19098018 |
2009 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The elevated systemic levels of selected proinflammatory cytokines, including those representing products of inflammasome activation, were associated with the CC at-risk variant of the Y402H polymorphism and suggest that genetic factors regulate the inflammatory status in dry AMD patients.
|
24083687 |
2013 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Pooled overall odds ratios for RAP/AMD were 1.15 (95% CI 0.60-2.18) for GT versus GG, 3.52 (95% CI 1.25-9.91) for TT versus GG ARMS2, 0.98 (95% CI 0.22-4.29) for GA versus AA, 1.00 (95% CI 0.25-4.02) for GG versus AA CFHI62V, 0.57 (95% CI 0.35-0.93) for CT versus TT CFH Y402H, and 0.40 (95% CI 0.22-0.74) for CC versus TT CFH Y402H.
|
28005184 |
2017 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data did not show significant association between the CFH Y402H polymorphism and PDT treatment response for neovascular AMD; however, CRP genetic variants were associated with a positive response to PDT treatment for neovascular AMD.
|
19692124 |
2009 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the present study, exudative AMD is not associated to serum VEGF165 levels; furthermore, our data does not establish a statistical link between VEGF165 and the CFH Y402H polymorphism.
|
21158586 |
2011 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Younger age of exudative AMD onset was associated with the homozygous AA genotype of IL-8 rs4073 (p = 0.009, Mann-Whitney U-test), CC genotype of CFH rs1061170 (p = 0.016), TT genotype of ARMS2 rs10490924 (p = 0.001) and with current smoking (p = 0.002).
|
26154559 |
2015 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population.
|
28641277 |
2019 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products.
|
18292785 |
2009 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ethnic variation in AMD-associated complement factor H polymorphism p.Tyr402His.
|
16865697 |
2006 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, higher levels of CRP in the presence of C allele of Y402H might confer more risk for the development of exudative AMD.
|
27778189 |
2017 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
AMD individuals who had at least one copy of the C allele of rs1061170 had an increased risk of disease compared with cases with the T allele.
|
25612476 |
2016 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was a trend for association between the CFH Y402H T allele ("low risk" for AMD, n = 6) and improvement.
|
24113783 |
2013 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant difference in the incidence of CFH Y402H (P = 0.598) and HTRA1 rs11200638 (P = 0.290) between eyes with typical exudative AMD and with PCV.
|
18939352 |
2008 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
The joint effects for complement factor H (CFH) Y402H and 10q26 variants indicated an increased risk of exudative AMD.
|
20456446 |
2010 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
Y402H polymorphism which has been suggested to be a major risk factor of AMD in Caucasians was found to be only marginally associated with exudative AMD with low frequency, whereas three adjacent SNPs in the CFH gene were significantly associated with AMD in Koreans.
|
18223247 |
2008 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the CFH gene, the frequency of the previously reported Tyr402His variant was not significantly higher in the AMD group than in the control group (P = .31).
|
17157600 |
2006 |
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation
|
BEFREE |
CFH Y402H SNP might be protective for AMD in the Turkish population.
|
27404493 |
2016 |